Cited by 559Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Globular amyloid β‐peptide 1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease

Barghorn, Stefan, Nimmrich, Volker, Striebinger, Andreas, Krantz, Carsten, Keller, Patrick, Janson, Bodo, Bahr, Michael, Schmidt, Martin +5 more·2005·Journal of Neurochemistry

Abstract

Amyloid beta-peptide (Abeta)(1-42) oligomers have recently been discussed as intermediate toxic species in Alzheimer's disease (AD) pathology. Here we describe a new and highly stable Abeta(1-42) oligomer species which can easily be prepared in vitro and is present in the brains of patients with AD and Abeta(1-42)-overproducing transgenic mice. Physicochemical characterization reveals a pure, highly water-soluble globular 60-kDa oligomer which we named 'Abeta(1-42) globulomer'. Our data indicate that Abeta(1-42) globulomer is a persistent structural entity formed independently of the fibrillar aggregation pathway. It is a potent antigen in mice and rabbits eliciting generation of Abeta(1-42) globulomer-specific antibodies that do not cross-react with amyloid precursor protein, Abeta(1-40) and Abeta(1-42) monomers and Abeta fibrils. Abeta(1-42) globulomer binds specifically to dendritic processes of neurons but not glia in hippocampal cell cultures and completely blocks long-term potentiation in rat hippocampal slices. Our data suggest that Abeta(1-42) globulomer represents a basic pathogenic structural principle also present to a minor extent in previously described oligomer preparations and that its formation is an early pathological event in AD. Selective neutralization of the Abeta globulomer structure epitope is expected to have a high potential for treatment of AD.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2005.03407.x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In hippocampal slices, synthetic Aβ oligomers cause rapid LTP inhibition.

    “In hippocampal slices, synthetic oligomers cause rapid LTP inhibition (Barghorn et al., 2005; Fa et al., 2010; Jurgensen et al., 2011; Lambert et al., 1998; Nimmrich et al., 2008; Rammes et al., 2011; Wang et al., 2002).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., Barlow, E., Ebert, U., & Hillen, H.
Affiliations
  • Abbott (Germany) (DE)
  • Abbott (United States) (US)
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2005-08-31
Volume
95
Issue
3
Pages
834-847
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2126958454
Cited by
559
References
41
Citations by year
2026: 7 · 2025: 14 · 2024: 12 · 2023: 19 · 2022: 19 · 2021: 21 · 2020: 18 · 2019: 21 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 19 · 2014: 29 · 2013: 40 · 2012: 40
FWCI
17.78
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid beta peptide 1-42, amyloid-beta oligomers, Alzheimer's disease, antigenic determinants, long-term potentiation, hippocampus, transgenic mice, neurotoxicity
MeSH terms
Alzheimer Disease, Animals, Antibodies, Antibody Specificity, Epitopes, Cells, Cultured, Fatty Acids, Hippocampus, Humans, Male, Mice, Transgenic, Neurons, Peptide Fragments, Protein Conformation, Rabbits, Solubility, Water, Amyloid beta-Peptides, Rats, Sprague-Dawley, Long-Term Potentiation, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review